-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Interleukin 17 subtypes, interleukin 17A and interleukin 17F are related to the pathophysiology of psoriasis and are overexpressed in psoriasis tissues.
Recently, researchers compared the therapeutic effects of Bimekizumab with the selective interleukin 17A inhibitor Secukinumab in the treatment of moderate to severe plaque psoriasis.
This study is a phase III clinical study.
743 patients participated in the study, including 373 in the Bimekizumab group and 370 in the Secukinumab group.
At 16 weeks, the PASI100 response rate was 61.
The study found that for patients with moderate to severe plaque psoriasis, the clinical effect of bimekizumab, a dual interleukin 17A/17F inhibitor, is better than the choice of interleukin 17A inhibitor Secukinumab, but the risk of oral Candida infection is higher .
For patients with moderate to severe plaque psoriasis, the clinical effect of bimekizumab, a dual interleukin 17A/17F inhibitor, is better than the choice of interleukin 17A inhibitor Secukinumab, but the risk of oral Candida infection is higher.
Original source:
Kristian Reich et al.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
Leave a message here
